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Transduction of peptide analogs of the small heat
shock–related protein HSP20 inhibits intimal
hyperplasia
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Furnish, PhD,b William Stone, MD,a Richard Fowl, MD,a and Colleen M. Brophy, MD,b,c
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Background: Human saphenous vein (HSV) is the autologous conduit of choice for peripheral vascular reconstructions.
However, vasospasm can lead to early graft failure. The leading cause of delayed graft failure is intimal hyperplasia.
Objective: To develop a proteomic approach to prevent vein-graft spasm and intimal hyperplasia.
Methods: Biomimetic peptide analogs of the small heat shock–related protein HSP20, containing a protein transduction
domain (PTD), a phosphorylated serine, and a sequence of HSP20 surrounding the phosphorylation site (PTD-
pHSP20), or a scrambled sequence of the same amino acids surrounding the phosphorylation site (PTD-scHSP20) were
synthesized. The peptides were used in muscle bath and organ culture experiments with human saphenous vein (HSV)
segments. Cultured smooth muscle cell lines were used to determine the effect of the peptides on proliferation and
migration.
Results: In HSV rings precontracted with norepinephrine, PTD-pHSP20 but not PTD-scHSP20 led to relaxation. There
was no significant difference in smooth muscle cell proliferation in cells treated with PTD-pHSP20 compared with
PTD-scHSP20. Treatment with PTD-pHSP20 significantly inhibited cellular migration compared with PTD-scHSP20.
Control, untreated, and PTD-scHSP20–treated saphenous veins had significant increases in intimal thickness after
culture. This intimal thickening was completely inhibited by treatment with PTD-pHSP20.
Conclusions: Protein transduction of biologically active motifs of HSP20 can affect pathologic and physiologic responses
of HSV and represents a novel proteomic-based therapeutic approach. (J Vasc Surg 2004;40:106-14.)
Clinical Relevance: We have been a part of the genomics era and are now viewing the emergence of “proteomics.” The
genome is linear and relatively easy to examine; however the proteome is much more complex and dynamic. In essence, the
purpose of gene therapy is to manipulate the genome to produce a particular protein. This manuscript describes a new
proteomic approach in which the biologically active part of a protein is directly introduced into vascular cells. Peptides
were synthesized which contained a total of 24 amino acids, 11 of which represent a protein transduction domain or
“carrier” while the other 13 are the biologically active “cargo.” These synthetic peptides prevent spasm (contraction) and
intimal hyperplasia in segments of human saphenous vein treated ex vivo. Preclinical development is currently underway
to develop these molecules as a proteomic-based vein harvest solution to enhance vein-graft patency.One of the ideal conduits for peripheral vascular and
coronary reconstruction is the greater saphenous vein.
However, surgical manipulation during harvest of the con-
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doi:10.1016/j.jvs.2004.03.028106duit leads to vasospasm. This vasospasm is arrested by
mechanical distension of the graft, which leads to injury and
subsequent intimal hyperplasia, which contribute to both
early and long-term graft failure.1,2 The development of
vein-graft stenoses occurs in 20% to 40% of grafts and can
lead to end-organ failure, including myocardial infarction
and extremity amputation.3-5 The leading cause of vein-
graft failure is intimal hyperplasia,6 which is a complex process
but primarily involves a smooth muscle cell (SMC) response
to injury. Intimal hyperplasia involves alterations in SMC
phenotype, resulting in cells that proliferate, migrate, and
produce matrix proteins.7 This hyperplastic response nar-
rows the lumen of the vessel and leads to graft failure.
The exact etiology of vein-graft spasm is complex and
most likely multifactorial. Most investigations have sug-
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tion or impaired relaxation of the vascular smooth muscle
in the media of the vein. Vasorelaxants such as nitric oxide
(NO), sodium nitroprusside, and forskolin lead to activa-
tion of either cGMP or cAMP, which subsequently activate
cGMP-dependent protein kinase (PKG) or cAMP-depen-
dent protein kinase (PKA), respectively. HSP20 has re-
cently been identified as a substrate protein of both PKG
and PKA.8 HSP20 is highly and constitutively expressed in
muscle tissues and shares considerable sequence homology
to the other small heat shock proteins (eg, HSP27), myo-
tonic dystrophy kinase binding protein, and the crystallins.9
Increases in the phosphorylation of HSP20 are associated
with cyclic nucleotide-dependent relaxation of vascular
smooth muscle and inhibition of agonist-induced contrac-
tion of smooth muscle.8,10
There are numerous endogenous mediators of intimal
hyperplasia, including nitric oxide (NO), a potent activator
of guanylate cyclase. Activation of cGMP pathways with
NO and NO donors has been demonstrated to inhibit
proliferation,11,12 migration,13 and intimal hyperpla-
sia.14-18 The addition of cyclic nucleotides or the inhibition
of their breakdown results in decreased vascular SMC pro-
liferation,19-21 migration,22 and intimal hyperplasia.23 Hy-
perplastic lesions express lower levels of cGMP than normal
vessels.24,25 Recently, we have determined that phenotypic
modulation in rat aortic SMCs in culture is associated with
a down regulation of both PKG and the small heat shock-
related protein HSP20. SMCs that are stably transfected
with PKG re-express both PKG and HSP20.20 Both bio-
chemical and physiologic analyses demonstrate that these
cells revert to a contractile phenotype.20,26 Taken together,
these findings support a role for the cyclic nucleotide-
dependent signaling pathways in mediating the processes
that lead to intimal hyperplasia.
Gene therapy has been advocated as an approach to
prevent intimal hyperplasia. For example, the introduction
of nitric oxide synthase with adenoviral transfection has
been shown to reduce intimal hyperplasia.27 However,
there are significant limitations of gene therapy, including
targeting the appropriate cells,28 difficulty in obtaining
high transfection rates,29 immunogenicity of the viral vec-
tors,30 and in regulation of the expression of the gene
product.27,31 An alternate approach involves directly trans-
ducing peptides or proteins across cell membranes by link-
ing a variety of arginine rich peptides to biologically active
cargo proteins or peptides. The hypothesis of this study was
that protein transduction of HSP20 phosphopeptide ana-
logs would prevent spasm and intimal hyperplasia in human
saphenous vein.
METHODS
Materials. Fetal bovine serum, RPMI 1640, L-glu-
tamine, penicillin, and streptomycin were purchased from
Gibco (Grand Island, NY). All other reagent grade chemi-
cals were from Sigma (St. Louis, Mo).
Peptide synthesis and purification. Peptides con-
taining an 11-amino-acid protein transduction domain(PTD) of the TAT (YGRKKRRQRRR) or modified TAT
(YARAAARQARA) sequence were fused to either the
functional 13-amino-acid sequence (WLRRApSAP-
LPGLK, where pS denotes phosphoserine)32 of HSP20
(PTD-pHSP20) or a scrambled HSP20 sequence
(PRKpSLWALGRPLA, PTD-scHSP20) and were synthe-
sized by Cell essentials (Boston, Mass) or at Arizona State
University. Fluorescein isothiocyanate (FITC)–labeled
peptides were synthesized by linking FITC to beta-alanine
added at the N-terminus of the peptide. Peptides were
synthesized by using standard solid phase peptide synthesis,
which uses standard Fmoc chemistry. Crude peptide was
purified by using reverse phase fast protein liquid chroma-
tography (Akta Explorer, Amersham Biosciences, Piscat-
away, NJ). A linear gradient of water/acetonitrile contain-
ing 0.1% trifluoroacetic acid was used with a C18 column
(Grace Vydac, Hesperia, Calif). Identification of peptides
was confirmed with MALDI-TOF or ESI-MS (Waters Cor-
poration, Milford, MA), and purity was evaluated by ana-
lytical reverse phase Alliance HT HPLC (Waters Corpora-
tion, Milford, Mass). Only peptides with molecular masses
identical to the predicted mass and95% purity were used.
The peptides were stored as the lyophilized powder or
prepared as 20 mmol/L stock solutions in sterile, deion-
ized water and aliquots stored at –20°C until use.
Procurement of vascular tissue. After obtaining ap-
proval of the Mayo Clinic Scottsdale Institutional Review
Board, excess segments of human saphenous vein were
obtained from patients undergoing peripheral bypass pro-
cedures. The veins were stored in a saline solution until the
end of the surgical procedure, at which time they were then
placed in N-(2-hydroxyethel)piperazine-N-(2-ethanesul-
foxic acid) buffer (10 mmol/L HEPES, pH 7.4; 140
mmol/L NaCl; 4.7 mmol/L KCl; 1.0 mmol/L MgSO4;
1.0 mmol/L NaH2PO4; 1.5 mmol/L CaCl2; and 10
mmol/L glucose) and stored on ice. All veins were cultured
within 2 hours after completion of the surgical procedure.
Using sterile technique, the veins were transferred to a
60-mm Petri dish under a sterile hood. The edges of each
vein (0.5 mm) were removed with a 10-blade scalpel.
Excess adventitial tissue and fat was removed with minimal
manipulation of the vein. The vein was then sectioned into
8 consecutive rings of approximately 1.0 mm in width, 6 for
organ culture or muscle bath experiments. Two segments
were immediately fixed in 10% formalin at 37°C for 30
minutes to obtain baseline data.
Physiologic measurements. Rings 1.0 mm in width
were cut from segments of saphenous vein. The tissue was
suspended in a muscle bath containing a bicarbonate buffer
(120 mmol/L NaCl, 4.7 mmol/L KCl, 1.0 mmol/L
MgSO4, 1.0 mmol/L NaH2PO4, 10 mmol/L glucose, 1.5
mmol/L CaCl2, and 25 mmol/L Na2HCO3; pH 7.4),
equilibrated with 95% O2/5% CO2 at 37°C. Force mea-
surements were obtained by using a Kent Scientific (Litch-
field, Conn) force transducer (TRN001) interfaced with a
Data Translation A-D board, DT2801 (Data Translation,
Inc, Marlboro, Mass). Data was acquired with Dasylab
software (Dasytec, Amherst, Mass). The rings were repeat-
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replacement of NaCl in bicarbonate buffer), and the length
was progressively adjusted until maximal tension was ob-
tained. The tissue was washed with bicarbonate buffer and
equilibrated for at least 30 minutes between contractions.
Any tissue failing to contract with norepinephrine was
considered nonviable and was not used in further experi-
ments. Rings of saphenous vein were precontracted with
norepinephrine (107 mol/L) for 10 minutes. Cumulative
increasing doses (0.1 - 1 mmol/L) of the PTD-pHSP20 or
PTD-scHSP20 peptides were then added to the baths and
the decrease in tension was measured. In a separate exper-
iment, rings of saphenous vein were pretreated with cumu-
lative doses (1-10 mmol/L) of PTD-pHSP20 peptide in
7.5% dextran gel for 10 minutes and then challenged with
norepinephrine (107 mol/L) and tension generated was
measured. At the end of the experiment, rings were washed
and contracted with KCl to check the viability of the tissues.
Localization of FITC-TAT-pHSP20 peptides. Swiss
albino 3T3 fibroblasts (ATCC, Manassas, Va) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10 % fetal bovine serum (FBS) on glass
coverslips. The cells were incubated in 0.5% FBS containing
medium for 1 hour and then treated with 25 mol/L
FITC-TAT-pHSP20 in the same medium for 30 minutes,
at 37°C. The cells were washed 3 times in phosphate
buffered saline, fixed in 4% paraformaldehyde, permeabil-
ized with 0.25% Triton X-100, and mounted on glass slides
using Prolong Antifade (Molecular Probes, Ore). Cells
were visualized with a Lecia DM RBE microscope. FITC
fluorophores were excited with a 488-nm argon ion laser
attenuated to 50% maximal emission and FITC emission
from 480 to 560 nm were collected using a prism spectro-
photometer. Confocal optical sections were acquired at
10-nm intervals with the Lecia SP2 software package. Pro-
jection images were complied from each z-series and saved
as 1024  1024-pixel digital images.
Organ culture of human saphenous vein. In a 48-
well culture dish (Falcon 3078, Becton-Dickinson, Frank-
lin Lakes, NJ) duplicate vein segments were cultured in 0.5
mL of media alone (RPMI-1640, 30% FBS, 100 U/mL
penicillin, 100 U/mL streptomycin, 2 mmol/L L-glu-
tamine), or in media containing 10 mol/L of PTD-
pHSP20 or PTD-scHSP20. The veins were cultured at
37°C in a humidified atmosphere with 5% (v/v) CO2 in air
for 14 days. Media was changed every 2 to 3 days with fresh
peptides added (10 mol/L) with each media change.
Vessel morphometry. After 14 days of organ culture,
vein segments were fixed in 0.5 mL of 10% formalin at 37°C
for 30 minutes. Vein segments were then embedded in
paraffin for sectioning. Beginning at the midportion of each
ring, 5 transverse sections, spread 5 m apart, were cut for
each specimen. Each section was then stained with Ver-
hoeff-van Gieson stain. Measurements of intimal thickness,
intimal area, and medial area were made on each transverse
section with a computerized image analysis system (Scion
Image, Frederick, Md). Each section was examined by
using light microscopy (Carl Zeiss, Thornwood, NY), and6 measurements of intimal thickness were randomly taken
from each section (total of 30 measurements for each ring).
Intima was defined as tissue on the luminal side of the
internal elastic lamina or the chaotic organization of the
cells contained within it, whereas the medial layer was
contained within the intimal layer and the external elastic
lamina. Intimal and medial area was measured for each
section at 5magnification and the intimal-to-medial ratio
(I/M) was calculated (intimal area/[intimal area  medial
area]). The average I/M ratio for each ring was then
calculated.
To assess distribution of fluorescent peptides in tissue,
veins were treated prior to sectioning with FITC-labeled
peptides as described previously. Sections were imaged with
a fluorescent microscope.
Cell culture. A10 SMCs were purchased from Amer-
ican Type Culture Collection (Manassas, Va) and main-
tained in Dulbecco’s modified Eagle’s medium supple-
mented with 4 mmol/L L-glutamine, 4.5 g/L glucose, 1.0
mmol/L sodium pyruvate, and 1.5g/L sodium bicarbon-
ate and 10% fetal bovine serum (FBS). Cells were incubated
at 37°C, 5% (v/v) CO2 in air.
Proliferation assay. Proliferation was determined by
using 3H-thymidine to measure DNA synthesis as previ-
ously described.22 Briefly, confluent A10 cells in 100-mm
dishes were detached with 0.5% trypsin/EDTA, seeded
onto 24-well plates (10,000 cells/well) in 10% FBS media,
and allowed to attach overnight. SMCs were starved in a
0.5% FBS media for 72 hours, then incubated for 24 hours
with growth factor PDGF-BB (25 ng/mL) and peptides as
indicated. During the final 4 hours of the assay, 2 Ci of
[methyl-3H]-thymidine was added to each well. Incorpo-
rated 3H-thymidine was precipitated with 10% trichloro-
acetic acid and counted with a liquid scintillation counter.
Migration assay. A Boyden chamber assay was per-
formed to measure SMC migration. A10 cells were seeded
in 60-mm dish (300,000/plate, 100% confluent) in a
10% FBS media. The next day, the cells were changed to
media containing 0.5% FBS and incubated for 48 hours.
During the last 15 hours of low-serum incubation, PTD-
pHSP20 or PTD-scHSP20 (50 mol/L) were added to
the cells. Cells were harvested by trypsinization and used in
a 3-hour transwell assay. Cells (80,000 cells/well) were
loaded in the upper chamber of the transwell (8 m,
Corning Inc, Corning, NY), separated from the lower
chamber by a porous membrane, in media containing 0.5%
FBS with either PTD-pHSP20, PTD-scHSP20, or no pep-
tide. Media containing 10% FBS or 0.5% FBS was added to
the lower chamber. The transwells were then incubated for
3 hours. The membrane was subsequently removed, fixed
with 70% ethanol, and stained with hematoxylin. After
removing the cells on the upper surface (cells that did not
migrate) and mounting the membrane on a glass slide, cells
on the lower surface (migrated cells) were counted under a
microscope. These experiments were performed in tripli-
cate, with the average values used in statistical analyses.
Statistical analysis. Results are expressed as mean 
SEM. Statistical differences between control and the treat-
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variance with the Tukey test for multiple comparisons
(SigmaStat; SPSS, Chicago, Ill). The criteria for signifi-
cance was P 	 .05.
RESULTS
Phosphopeptide analogs of HSP20 relax human
saphenous vein. To determine if phosphorylated HSP20
has a role in the relaxation of saphenous vein smooth
muscle, rings were precontracted with norepinephrine
(107 mol/L). This dose was sufficient to cause submaxi-
mal contraction, as determined from cumulative dose re-
sponse curves (data not shown). Transduction of precon-
tracted rings of saphenous vein with the PTD-pHSP20
Fig 1. Transducible HSP20 phosphopeptide analogs rel
suspended in a muscle bath and were precontracted with
increasing doses (0.1 - 1 mmol/L) of the PTD-pHSP20
then added. The percentage of relaxation was calculated
the force after the addition of the peptide divided by the
3, *P 	 .05 compared to PTD-scHSP20). B, Rings of
mmol/L) of PTD-pHSP20 peptide in 7.5% dextran gel
mol/L). C, Histologic representation of transduction o
strips were treated with 100 mol/L PTD-FITC-pH
paraformaldehyde, paraffin embedded, and 6-m sectio
fluorescence microscopy.phosphopeptide led to a dose-dependent decrease in force,
whereas PTD-scHSP20 had no significant effect on con-
tractile force (Fig 1,A). To determine if pretreatment of the
vein grafts with phosphopeptide analogs of HSP20 would
prevent spasm (contraction), saphenous vein rings were
coated with 7.5% dextran gels containing PTD-pHSP20
peptides. The rings were then submerged into baths contain-
ing norepinephrine (Fig 1, B). The gels containing the PTD-
pHSP20 analogs inhibited norepinephrine-induced contrac-
tion in a dose-dependent manner. To determine if the
peptides were penetrating the tissues, strips of saphenous
vein were treated with FITC-PTD-pHSP20 for 30 minutes
and then fixed in paraformaldehyde, embedded in paraffin,
sectioned, and viewed under fluorescence microscopy. Flu-
uman saphenous vein. A, Rings of saphenous vein were
epinephrine (107 mol/L) for 10 minutes. Cumulative
D-P20) or PTD-scHSP20 peptides (PTD-ScP20) were
force of the maximal norepinephrine contraction minus
of the maximal norepinephrine contraction  100 (n

nous vein were pretreated with cumulative doses (1-10
0 min and then challenged with norepinephrine (107
C-labeled peptides into saphenous vein. Representative
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that the peptide permeated the tissue (Fig 1, C).
Localization of PTD-pHSP20 peptides. To deter-
mine the distribution of PTD pHSP20 peptides, Swiss
albino 3T3 cells were treated with FITC-labeled peptides
for 30 minutes, then fixed in paraformaldehyde, permeabil-
ized, and analyzed by confocal microscopy. Confocal pro-
jection and single optic section images confirmed the pres-
ence of peptides within the cells. The transduction
efficiency was greater than 90%, with a diffused distribution
of peptides throughout the cell (Fig 2, B). There was some
punctate staining, which probably represents endocytic ves-
icles along with nuclear staining. (Fig 2, B). The control
cells with no peptide treatment demonstrated very little
autofluorescence (Fig 2, A).
The effect of phosphopeptide analogs of HSP20 on
SMC proliferation. Platelet-derived growth factor
(PDGF) is a potent stimulator of SMC proliferation. In
these experiments PDGF-BB was added to culture media
along with the peptides analogs to determine if PTD-
pHSP20 inhibits SMC proliferation. DNA synthesis, a
measure of proliferation, was then quantified. Treatment of
A10 SMCs with PDGF led to increased SMC proliferation
compared with the controls (2984.6 134.9 cpm vs 1503
 90.8 cpm). There was no significant difference in DNA
Fig 2. Localization of FITC-PTD-phospho HSP20 p
25mol/L FITC-PTD-pHSP20 peptides for 30 minute
confocal microscopy. A representative optical section t
intervals is depicted here. Non-peptide–treated contro
analogs (B). FITC-PTD-pHSP20 peptides localization
staining consistent with a vesicular distribution (arrow),synthesis in PDGF-BB stimulated cells compared with cells
treated with PDGF-BB in the presence of the PTD-
scHSP20 or PTD-pHSP20–treated cells (2823.5  112.8
cpm and 3448  128.2 cpm, respectively). These data
suggest that phosphopeptide analogs of HSP20 have no
significant effect on SMC proliferation.
The effect of phosphopeptide analogs of HSP20 on
SMC migration. A modified Boyden chamber assay was
performed to determine the effect of phosphopeptide ana-
logs of HSP20 on smooth muscle migration. A10 SMCs
were incubated in the presence of PTD-scHSP20 or PTD-
pHSP20. A concentration gradient of serum was developed
within the chamber to induce migration across the mem-
brane. At the completion of the assay, migrated cells from 4
high-power fields were counted under regular Nikon light
microscope at 200. The mean number of migrated cells
for the control (no FBS stimulation), FBS, PTD-scHSP20
 FBS, and PTD-pHSP20 FBS groups were 61.3 6.8,
322.3 33.1, 229.0 16.2, and 79.6 14.8, respectively
(Fig 3). A10 cells treated with FBS alone and PTD-
scHSP20  FBS showed significant increases in migration
over the control group (P 	 .001). In sharp contrast,
PTD-pHSP20 inhibited cellular migration by 93% com-
pared with the FBS group (P 	 .001), and by 89% com-
pared with cells treated with PTD-scHSP20  FBS (P 	
e analogs. Swiss albino 3T3 cells were treated with
°C as described in the methods section and analyzed by
from a confocal projection image, sectioned at 10-um
(A). Cells treated with FITC-PTD-pHSP20 peptide
iffuse throughout cytoplasm. There was also punctate
with nuclear staining (arrow). Scale bar 200 m.eptid
s at 37
aken
l cells
was d
along
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the number of migrated cells between the control and
PTD-pHSP20 FBS treated cells. These data suggest that
phosphopeptide analogs of HSP20 inhibit cellular
migration.
The effect of phosphopeptide analogs of HSP20 on
intimal hyperplasia in a human saphenous vein organ
culture model. Since smooth muscle migration has been
implicated in the processes leading to intimal hyperplasia,
the effects of phosphopeptide analogs of HSP20 on intimal
hyperplasia were determined. Six human saphenous veins,
36 rings total (12 each for control, PTD-scHSP20, and
PTD-pHSP20), were cultured for 14 days in the presence
of 30% serum. These high serum concentrations induce a
hyperplastic response (n 
 15). All veins were deemed
viable at the time of culture by adequate contraction with a
norepinephrine challenge in a muscle bath. The average
intimal thickness of the precultured veins was 25.4  7.8
m. After culture the average intimal thickness of the
control and PTD-scHSP20–treated veins was 58.4  7.2
m and 60.7  8.5 m, respectively, while that of the
PTD-pHSP20 treated veins was 24.7  4.2 m (Fig 4, A,
B). The control and PTD-scHSP20–treated veins showed a
57% and 58% increase in intimal thickness compared with
preculture (P 
 .05; P 
 .04, respectively). PTD-
pHSP20–treated veins had an intimal thickness that was
not significantly different from the precultured veins. There
Fig 3. Phospho HSP20 peptides inhibit migration of smooth
muscle cells. A10 cells in the upper transwell chamber were treated
with either 0.5% FBS alone or in combination with PTD-scHSP20
or PTD-pHSP20. Migration against a serum gradient was deter-
mined by placing 10% FBS into the lower chamber. No serum
gradient (0.5% FBS) was used for the control. Four separate
experiments were performed. No significant difference was found
between control cells and PTD-pHSP20 FBS-treated cells (#P
.05). PTD-pHSP20 significantly inhibited migration over both
FBS and PTD-scHSP20  FBS-treated cells (*P 	 .05).were no differences in medial thickness of the rings after
culture with the peptides. In addition, intimal thickness was
determined as an I/M ratio. PTD-pHSP20 treatment does
not significantly increase the I/M ratio above preculture
levels (0.08  0.01 and 0.12  0.01, respectively; P 

.695), whereas both control (0.31  0.03; P 	 .001) and
PTD-scHSP20 treatment (0.36 0.01; P	 .001) leads to
significant increases in the I/M ratio (Fig 4, C). Similarly,
although there was no difference in I/M ratio between the
control and PTD-scHSP20 treatment (P
 .24), there was
a significant decrease between PTD-pHSP20 treatment
and both the control (P 	 .001) and PTD-scHSP20 treat-
ment (P 	 .001). These data suggest that phosphopeptide
analogs of HSP20 inhibit intimal hyperplasia in an organ
culture model of human saphenous vein.
DISCUSSION
This study presents a proteomic approach to the pre-
vention of vein-graft failure due to spasm and intimal
hyperplasia. Previously, protein and peptide therapeutic
approaches have targeted cell membrane receptors or sig-
naling pathways.33 This study used transduction domains
fused to biologically active peptide motifs to target down-
stream post-translational modifications on effector pro-
teins. In many pathologic states, the molecules that com-
prise the receptors and/or signaling pathways may be
downregulated or physiologically ineffective for a variety of
reasons. Directly transducing the downstream effector mol-
ecule bypasses receptors and the signaling pathways acti-
vated by the receptors and restores the specific aspect of the
proteome that is activated by these upstream modulators.
Given the considerable cross talk between signaling path-
ways, directly restoring only the downstream portion of the
proteome also confers specificity to the cellular response.
We used phosphopeptide analogs of HSP20 to deter-
mine if relaxation could be induced in precontracted hu-
man saphenous vein. Relaxation was induced in the vein
segments by phosphopeptide analogs of HSP20 which
contained (1) a protein transduction domain (PTD), (2)
the amino acid sequence surrounding the phosphorylation
site of the HSP20, and (3) a phosphoserine at the phos-
phorylation site (Fig 1). Relaxation was measured as iso-
metric tension. We had demonstrated earlier that the trans-
duction of PTD-phosphoHSP20 analogs relaxed bovine
carotid artery precontracted with serotonin.34 Further
studies demonstrated that transduction of porcine coronary
artery with PTD-pHSP20 peptides led to dose-dependent
relaxation while peptides containing the protein transduc-
tion domain coupled with a random orientation of the same
amino acids did not. Mass spectrometric immunoassays of
smooth muscle homogenates after treatment with the
PTD-pHSP20 peptides demonstrated that the peptides did
not induce phosphorylation of the endogenous HSP20.35
This suggests that the PTD-phosphoHSP20 peptide alone
is sufficient to inhibit force maintenance and is likely having
a direct effect on the target of phosphorylated HSP20.
Thus, synthetic oligopeptides can be engineered to enter
JOURNAL OF VASCULAR SURGERY
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HSP20 molecule (relaxation).
Impaired smooth muscle relaxation may contribute to
vein-graft spasm. To arrest vein-graft spasm, surgeons often
mechanically distend vein grafts by pressurizing the graft
with fluid. This mechanical distension leads to injury, which
promotes intimal hyperplasia.1,2 Thus, modalities that
would prevent spasm would likely reduce intimal hyperpla-
sia. Cyclic nucleotide-dependent signaling pathways have
been implicated in modulating intimal hyperplasia as well as
SMC relaxation. Therefore, we examined the effect of
phosphopeptide analogs on processes leading to hyperpla-
sia.
First, the effect of the synthetic peptides on SMC
proliferation and migration were determined. The PTD-
pHSP20 fusion peptide significantly inhibited cellular mi-
gration but not proliferation compared with PTD-
Fig 4. Phospho HSP20 peptides inhibit intimal hyperp
cultured for 14 days in media alone (control) or media
culture several rings from each vein were fixed in forma
compared to preculture (#P  .05) and significantly
PTD-scHSP20-treated veins (*P	 .05). B, Representati
vein stained with Verhoeff-van Gieson stain. The thickne
on the left of each image and is approximately 50 m in
calculated [intimal area/(intimal area  medial area)] fo
veins demonstrated a significant increase in the I/M ra
maintained the I/M ratio compared to pre-culture (#P scHSP20 peptide controls (Fig 3), suggesting that
phosphopeptide analogs of HSP20 modulate processes rel-
evant to SMC motility and contraction rather than those
processes at the level of the cell cycle. Since smooth muscle
migration is thought to be an initial event in intimal hyper-
plasia, the effect of the peptides on a human vein-graft
model of intimal hyperplasia was determined.
Human saphenous veins demonstrate increases in inti-
mal thickness and in I/M ratios when exposed to high
concentrations of serum in culture.15,36,37 Treatment with
phosphopeptide analogs of HSP20 significantly inhibited
intimal hyperplasia compared with both the control and
scrambled peptides (Fig 4). In addition, veins treated with
the peptide analogs preserved the I/M ratio, whereas the
control and scrambled HSP20-treated veins showed a sig-
nificantly increased I/M ratio. Because the veins were
treated with the peptide analogs throughout the culture
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would also prevent intimal hyperplasia. However, several
studies have suggested that prevention of the initial events
at the time of vein grafting (which lead to the injury
response) would be adequate to prevent intimal hyperpla-
sia.38 Taken together, these and other data suggest that
HSP20 may have a role in phenotypic modulation,27 in
SMC migration, and in directly inhibiting intimal hyperpla-
sia. The data indicating that the peptide analogs have no
effect on proliferation but inhibit hyperplasia, suggest that
migration may be a more relevant process to the develop-
ment of intimal hyperplasia than proliferation.
The exact mechanism by which phosphopeptide ana-
logs of HSP20 inhibit contraction, migration, and intimal
hyperplasia is not known. Previous studies have suggested
that phosphorylation induces alterations in the activity of
proteins by either altering the tertiary conformation of the
protein or by a direct interaction of the phosphorylated
domain and other intracellular molecules.39,40 Since the
peptide domain sequence from HSP20 is only 13 amino
acids in length, it is unlikely that there is significant confor-
mation associated with the peptide analogs. Structural anal-
ysis of PTD-HSP20 based on circular dichroism results and
modeling using both ProteinShop (Lawrence Berkley Na-
tional Laboratory)41 and Insight II (MSI Inc) indicated
that the PTD-pHSP20 peptide possessed a random coil
structure (Brophy, unpublished data). Treatment of cul-
tured cells with PTD-pHSP20 leads to loss of actin stress
fibers and focal adhesions.42 The peptide sequence
RRAS*AP closely resembles a 14-3-3 binding motif.43
14-3-3 proteins have been shown to associate with phos-
phorylated cofilin.44 When cofilin becomes dissociated
with 14-3-3 proteins, it becomes dephosphorylated and
activated as an actin depolymerizing protein. Thus, one
compelling possibility is that the peptides compete with the
association of cofilin with 14-3-3.44 This suggests that the
HSP20 analogs alter cellular function by means of a thin
filament regulatory process. In addition, this mechanism
suggests that the phosphopeptide analogs are exhibiting
their effects by altering intracellular protein-protein inter-
actions.
Further ex vivo and in vivo studies are needed to
determine the clinical applicability of this approach. How-
ever, the vein graft is an ideal target for proteomic-based
therapeutics in that the graft can be treated in a localized
manner, ex vivo, prior to implantation. This obviates the
problems of targeting associated with protein transduc-
tion.45 Because protein transduction is relatively new, pre-
vious investigations have concentrated on animal models to
characterize protein delivery and toxicity.45,46 Addition-
ally, studies of protein transduction on human tissue have
been focused at the cellular level.47,48 This study is the first
to demonstrate the effectiveness of protein transduction in
preventing a pathologic response in intact human tissue,
suggesting that HSP20 may be an ideal effector molecule
to target as a therapeutic approach for enhancing vein-graft
patency by preventing intimal hyperplasia.REFERENCES
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